Cardiff Oncology Stock Forward View - Simple Regression
| CRDF Stock | USD 1.80 -0.02 -1.10% |
Cardiff Oncology's Simple Regression reference page covers the model's projected value and error measures from recent price data. The forecast output and associated deviation metrics are shown for informational use. The model is fitted to available historical daily prices for Cardiff Oncology. This page is updated as new daily closing prices become available for Cardiff Oncology.
The Simple Regression forecasted value of Cardiff Oncology on the next trading day is expected to be 1.43 with a mean absolute deviation of 0.35 and the sum of the absolute errors of 21.07.In general, regression methods applied to historical equity returns or prices series is an area of active research. In recent decades, new methods have been developed for robust regression of price series such as Cardiff Oncology historical returns. These new methods are regression involving correlated responses such as growth curves and different regression methods accommodating various types of missing data. All Simple Regression forecast figures shown for Cardiff Oncology are reference data reflecting model output based on available historical prices. Simple Regression Price Forecast For the 23rd of March
Given 90 days horizon, the Simple Regression forecasted value of Cardiff Oncology on the next trading day is expected to be 1.43 with a mean absolute deviation of 0.35 , mean absolute percentage error of 0.15 , and the sum of the absolute errors of 21.07 .Please note that although there have been many attempts to predict Cardiff Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Cardiff Oncology's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Cardiff Oncology | Cardiff Oncology Price Prediction | Research Analysis |
Forecasted Value
The next-day forecast for Cardiff Oncology focuses on identifying predictive downside and upside bands that can frame a realistic trading range. No forecasting approach has been shown to beat all others over time. Investors should treat any model output as a guide, not a guarantee.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of Cardiff Oncology stock data series using in forecasting. Note that when a statistical model is used to represent Cardiff Oncology stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 116.2406 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.3454 |
| MAPE | Mean absolute percentage error | 0.1784 |
| SAE | Sum of the absolute errors | 21.0692 |
Other Forecasting Options for Cardiff Oncology
Bollinger Bands applied to Cardiff Stock price data measure how far Cardiff has deviated from its recent average relative to its own volatility. This distinction drives the choice of forecasting model applied to Cardiff Oncology's price data. On-balance volume for Cardiff Stock creates a running indicator of buying versus selling pressure in Cardiff. Price departures from the channel boundary often mean-revert, offering tactical signals for Cardiff Oncology's.Cardiff Oncology Related Equities
These stocks within the Health Care space are often compared to Cardiff Oncology by analysts and fund managers in the sector. Revenue and margin checks across this group help investors set expectations for Cardiff Oncology's results. Falling behind peers on key ratios may signal headwinds or execution issues worth looking into.
| Risk & Return | Correlation |
Cardiff Oncology Market Strength Events
For investors tracking Cardiff Oncology, market strength indicators offer quantitative evaluation of stock behavior. By using these indicators, traders can make more informed decisions about when to buy or sell Cardiff Oncology. These indicators capture shifts in momentum that may precede significant price moves in Cardiff Oncology. These metrics provide actionable context for both entry and risk management decisions around Cardiff Oncology.
Cardiff Oncology Risk Indicators
Analyzing Cardiff Oncology's basic risk indicators provides investors with a structured view of the risk-return trade-off for cardiff stock. By identifying the level of risk embedded in Cardiff Oncology's investment, investors can make informed decisions about position sizing. Analyzing Cardiff Oncology's risk indicators gives investors important context for price forecasting. Understanding the risk in Cardiff Oncology's investment allows investors to make informed choices about mitigating exposure.
| Mean Deviation | 3.9 | |||
| Standard Deviation | 6.34 | |||
| Variance | 40.19 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Cardiff Oncology
Coverage intensity for Cardiff Oncology matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Cardiff Oncology Short Properties
A short-interest review of Cardiff Oncology provides context for understanding whether skepticism in the market is becoming more influential. The stronger read compares short sentiment with trend behavior, volume, and the broader market narrative.
| Common Stock Shares Outstanding | 66.8 M | |
| Cash And Short Term Investments | 58.3 M |